Details of the Drug
General Information of Drug (ID: DM8109D)
Drug Name |
Oxazolidin-(2Z)-ylideneamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
24665-93-8; amino oxazoline; 1,3-oxazolidin-2-imine; 4,5-dihydrooxazol-2-amine; Oxazolidin-(2Z)-ylideneamine; 2-oxazolamine, 4,5-dihydro-; 4,5-dihydro-1,3-oxazol-2-amine; CHEMBL69446; aminooxazoline; iminooxazolidine; NSC43138; 2-amino-2-oxazoline; AC1Q4UHD; AC1L61HW; 2-amino-4,5-dihydrooxazole; 2-Oxazolamine,4,5-dihydro-; CTK4F4142; DTXSID50285885; MolPort-023-198-771; YAXGBZDYGZBRBQ-UHFFFAOYSA-N; MolPort-006-013-450; BDBM50078037; NSC-43138; ZINC13588690; AKOS006221228; AKOS009159127; NE22687; MCULE-9912511107; AJ-64218; AJ-64217
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 86.09 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -0.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||